Paclitaxel-induced apoptosis in HeLa cells is serum dependent

Journal of Biochemical Toxicology

Volumn 11, Issue 4, 1996, Pages 183-188

  Maldonado, Vilma ^a   De Anda, Jose ^a   Meléndez Zajgla, Jorge ^a  

^a INSTITUTO NACIONAL DE CANCEROLOGÍA   (Mexico)

Author keywords

Apoptosis; Cervical Cancer; HeLa cells; Paclitaxel; PKA; PKC

Indexed keywords

8 ((4 CHLOROPHENYL)THIO)CYCLIC 3',5' AMP; 8-((4-CHLOROPHENYL)THIO)CYCLIC-3',5'-AMP; ANTINEOPLASTIC AGENT; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; DNA FRAGMENT; DRUG DERIVATIVE; NUCLEOTIDE; PACLITAXEL; PROTEIN KINASE C;

AGAR GEL ELECTROPHORESIS; APOPTOSIS; ARTICLE; BIOSYNTHESIS; CELL DIVISION; CELL SURVIVAL; CULTURE MEDIUM; CYTOLOGY; DNA DAMAGE; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; ENZYME INDUCTION; HELA CELL; HUMAN; MOLECULAR WEIGHT; NUCLEOSOME;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CELL DIVISION; CELL SURVIVAL; CULTURE MEDIA; CYCLIC AMP; CYCLIC AMP-DEPENDENT PROTEIN KINASES; DNA DAMAGE; DNA FRAGMENTATION; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROPHORESIS, AGAR GEL; ENZYME INDUCTION; HELA CELLS; HUMANS; MOLECULAR WEIGHT; NUCLEOSOMES; PACLITAXEL; PROTEIN KINASE C; THIONUCLEOTIDES;

EID: 0030334642     PISSN: 08872082     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1522-7146(1996)11:4<183::AID-JBT3>3.0.CO;2-G     Document Type: Article

References (31)

1. J. F. R. Kerr, C. M. Winterford, and B. V. Harmon (1994). Apoptosis. Cancer, 73, 2013-2026.
2. A. H. Wyllie (1992). Apoptosis (The 1992 Frank Rose Memorial Lecture). Br. J. Cancer, 67, 205-208.
3. S. W. Lowe, H. E. Ruley, T. Jacks, and D. Housman (1993). p53-Dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell, 74, 957-967.
4. F. Guérite-Voegelein, D. Guénard, and P. Potier (1987). Taxol and derivates: a biogenetic hypothesis. J. Natl. Prod., 50, 9-18.
5. W. B. Derry, L. Wilson, and A. Jordan (1995). Stoichiometric binding of taxol suppresses microtubule dynamics. Biochemistry, 34, 2203-2211.
6. P. B. Schiff, J. Fant, and S. B. Horwitz (1979). Promotion of microtubule assembly in vitro by taxol. Nature, 277, 665-667.
7. M. D. Brabander, G. Geuens, R. Nuydens, R. Willebrords, F. Aerts, J. D. Mey, and J. R. McIntosh (1986). Microtubule dynamics during the cell cycle: the effects of taxol and nocodazole on the microtubule system of Pt K2 cells at different stages of the mitotic cycle. Int. Rev. Cytol., 101, 215-273.
8. J. J. Manfredi, J. Parness, and S. B. Horwitz (1982). Taxol binds to cellular microtubules. J. Cell. Biol., 94, 688-695.
9. J. Parness, D. G. I. Kingston, R. G. Powell, C. Harracksingh, and S. B. Horwitz (1982). Structure-activity study of cytotoxicity and microtubule assembly in vitro by taxol and related taxanes. Biochem. Biophys. Res. Comm., 105, 1082-1089.
10. J. M. Andreu, J. F. Díaz, R. Gil, J. M. Pereda, M. G. Lacoba, V. Peyrot, C. Briand, E. Towns-Andrews, and J. Bordas (1994). Solution structure of taxotere-induced microtubules to 3-nm resolution. J. Biol. Chem., 269, 31785-31792.
11. E. Karantanis, S. Nicholson, and D. L. Morris (1994). Taxotere inhibits in vitro growth of human colonic cancer cell lines. Eur. J. Surg. Oncol., 20, 653-657.
12. E. K. Rowinsky, M. Wright, B. Monsarrat, and Donehower (1994). Clinical pharmacology and metabolism of TAXOL* (paclitaxel) Update. Ann. Oncol., 5, S7-S16.
13. A. D. Seidman (1994). Single-agent use of TAXOL* (paclitaxel) in breast cancer. Ann. Oncol., 5, S17-S22.
14. A. I. Einzing (1994). Review of phase II trials of TAXOL* (paclitaxel) in patients with advanced ovarian cancer. Ann. Oncol., 5, S29-S32.
15. D. H. Johnson, A. Y. Chang, and D. S. Ettinger (1994). TAXOL* (paclitaxel) in the treatment of lung cancer: The Eastern Cooperative oncology group experience. Ann. Oncol., 5, S45-S50.
16. A. A. Forastiere (1994). Current and future trials of TAXOL* (paclitaxel) in head and neck cancer. Ann. Oncol., 5, S51-S54.
17. K. Bhalla, Y. Huang, C. Tang, S. Seli, S. Ray, M. E. Mahoney, V. Ponnathpur, E. Tourkina, A. M. Ibrado, G. Bullock, and M. C. Willingham (1994). Characterization of a human myeloid leukemia cell line highly resistant to taxol. Leukemia, 8, 465-475.
18. C. Tang, M. C. Willingham, J. C. Reed, T. Miyashita, S. Rav, V. Ponnathpur, Y. Huang, M. E. Mahoney, G. Bullock, and K. Bhalla (1994). High levels of p26 BCL-2 oncoprotein retard taxol-induced apoptosis in human pre-B leukemia cells. Leukemia, 8, 1960-1969.
19. Y. Liu, K. Bhalla, C. Hill, and D. G. Priest (1994). Evidence for involvement of tyrosine phosphorylation in taxol-induced apoptosis in a human ovarian tumor cell line. Biochem. Pharmacol. 48, 1265-1272.
20. C. A. Burkhart, J. W. Berman, C. S. Swindell, and S. B. Horwitz (1994). Relationship between the structure of taxol and other taxanes on induction of tumor necrosis factor-α gene expression cytotoxicity. Cancer Res., 54, 5779-5782.
21. D. H. Pluznik, N. S. Lee, and T. Sawada (1994). Taxol induces the hematopoietic growth factor granulocyte-macrophage colony-stimulating factor in murine B-cells by stabilization of granulocyte-macrophage colony-stimulating factor nuclear RNA. Cancer Res., 54, 4150-4154.
22. H. C. Cheng, B. E. Kemp, R. B. Pearson, A. J. Smith, L. Misconi, S. M. van Patten, and D. A. Walsh (1986). A potent synthetic peptide inhibitor of the cAMP-dependent protein kinase. J. Biol. Chem., 261, 989-992.
23. M. Osmak and D. Eljuga (1993). The characterization of two human cervical carcinoma HeLa sublines resistant to cisplatin. Res. Exp. Med., 193, 389-396.
24. T. A. Willey, E. J. Bekos, R. C. Gaver, G. F. Duncan, L. K. Tay, J. H. Beijnen, and R. H. Farmen (1993). High-performance liquid chromatographic procedure for the quantitative determination of paclitaxel (Taxol) in human plasma. J. Chromat., 621, 231-238.
25. M. Frodin, P. Peraldi, and E. van Obberghen (1994). Cyclic AMP activates the mitogen-activated protein kinase cascade in PC12 cells. J. Biol. Chem., 269, 6207-6214.
26. M. Sandberg, E. Butt, Ch. Noite, L. Fischer, M. Halbriigge, J. Beltman, T. Jahnsen, H.-G. Geneiser, B. Jastorff, and U. Walter (1991). Characterization of Sp-5,6-dichloro-1-β-D-ribofuranosyl-bensimidazole-3′,5′- monophosphorothioate (Sp-5,6-DCl-cBiMPS) as a potent and specific activator of cyclic-AMP-dependent protein kinase in cell extracts and intact cells. Biochem. J. 279, 521-527.
27. V. Maldonado, J. Melendez, H. Gonzales, and A. Ortega (1995). Internucleosomal DNA cleavage in HeLa cells treated with cisplatin. Biochem. Mol. Biol. Int., 37, 691-696.
28. M. C. Willingham and K. Bhaila (1994). Transient mitotic phase localization of Bcl-2 oncoprotein in human carcinoma cells and its possible role in prevention of apoptosis. J. Histochem. Cytochem., 42, 441-450.
29. S. Lee S, S. Christakos S, and M. B. Small (1993). Apoptosis and signal transduction: clues to a molecular mechanism. Curr. Biol., 5, 286-291.
30. M. Kaszkin, G. Furstenberger, J. Richards, L. Seidler, and V. Kinzel (1991). A proposed mechanism by which phorbol esters and epidermal growth factor delay the progression from G2 phase to mitosis of HeLa cells through phospholipid metabolites. Cancer Res., 51, 4328-4335.
31. S. Wang and R. N. Pittman (1993). Altered protein binding to the octamer motif appears to be an early event in programmed neuronal cell death. Proc. Natl. Acad. Sci. U.S.A., 90, 10385-10389.